
|Videos|July 28, 2011
Dr. West on 4 Important Upcoming Clinical Trial Results
Author(s)H. Jack West, MD
Dr. Jack West from Swedish Cancer Institute Discusses 4 Important Upcoming Clinical Trials Results in Lung Cancer.
Advertisement
H. Jack West, MD, medical director of the Thoracic Oncology Program at the Swedish Cancer Institute in Seattle, Washington, discusses the anticipated results of 4 lung cancer clinical trials.
- FORIS-M trial examining the single agent use of talactoferrin in previously treated patients with non-small cell lung cancer (NSCLC).
- ECOG 1505 phase III trial looking at adjuvant chemotherapy with or without bevacizumab in completely resected NSCLC.
- RADIANT trial examining adjuvant erlotinib for EGFR-positive NSCLC patients, noteworthy because of its isolation of the EGFR mutation.
- The evaluation of the recombinant MAGE-A3 vaccine platform as adjuvant therapy in MAGE-A3-Positive NSCLC in addition to or instead of standard chemotherapy.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on OncLive
1
Long-Term Cilta-Cel Data Show Low Rates of PFS Events in Standard-Risk R/R Myeloma
2
Nonresponse to Bridging Therapy and Peak ALC After Cilta-Cel Are Associated With Neurotoxicity, NRM in Myeloma
3
FDA Updates Axi-Cel Label to Remove Limitation of Use in R/R PCNSL
4
Real-World Data Support Clinical Benefit With Lifileucel in Previously Treated Advanced Melanoma
5




































